$CymaBay Therapeutics (CBAY.US)$ Holding some good support a...

Holding some good support at this area long term. Spike in volume and price on 12/17. Has enough cash for approx 34 months after offering of $4/share which closed on the 11/22 I believe. Expecting Phase 2a data for short term still this year with time running out for MBX-2982 drug for Type 1 diabetes. Still undergoing enrollment on their main drug Seladelpar which is used for autoimmune liver disease with great outlook.

Institutional Holdings are around 60%ish+ according to Yahoo Finance/Ortex/and Finviz while Benzinga Pro reports Institutional Holdings at around 22%

Just back 11/11 Raymond James Maintained Strong Buy and raised PT to $14 with the average analyst PT at $11 where all are at Buy+

And a recent SC13G reported TCG Crossover Management having a 7% stake

Furthermore, according to their last earnings call, they will have sufficient funds to continue current operations into 2023 with no mentions of further dilution.